Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting

SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein, in a poster during the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from April 10^th to 15^th and May 17^th to 21^st.

Title:
The preclinical characterization of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein

Abstract Number: 972
Poster Number: 917

Session Category:
Antibody Technologies

Session Title:
Experimental and Molecular Therapeutics

Poster launch time: 
April 10th, 2021, 8:30 a.m.ET, U.S. time

About TST005
TST005, is a bi-functional anti-PD-L1 and TGF-β trap fusion protein designed to simultaneously target two immuno-suppressive pathways, transforming growth factor β-(TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor Type II protein in its C-terminal. TST005 lacks FcR binding and has reduced risk of FcR mediated killing of PD-L1 expressing effector T cells. TST005's PD-L1 high binding activity and enhanced TGF-β trap stability enables the targeted delivery of TGF-β trap into PD-L1 expressing tumors, thereby minimizing off-target toxicities of systemic inhibition of TGF-β signaling. TST005 displayed potent activity in vitro in reversing TGF-β induced T-cell suppression. In multiple syngeneic tumor models, TST005 induced significant increase of CD8 T-cell infiltration into PD-L1 expressing tumors and displayed dose-dependent tumor growth inhibition. TST005 is well tolerated in non-human primates and displayed a linear PK profile. TST005 is a potential novel bi-functional immunotherapy candidate with improved therapeutic window.

About Transcenta Holding Limited
Transcenta is a clinical stage global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. With Headquarters and Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston, US, Transcenta has established global footprint. Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Upon the latest financing, the company has raised over $342 million from globally prominent investors. For more information, please visit www.transcenta.com.

SOURCE Transcenta Holding Limited